CD4 and breast cancer: Summarized in Figure 3, Slamon’s 1987 paper holds the central position, with other seminal articles such as Von Minckwitz’s paper “Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer”, Geyer’s paper “Lapatinib plus capecitabine for HER2-positive advanced breast cancer”, and Goel’s paper, “Overcoming therapeutic resistance in HER2-positive breast cancers with CD4/6 inhibitors”.